Guide for medical professionals (i.e. dermatologists) for the management of Rhododenol‐induced leukoderma |
| |
Authors: | Chikako Nishigori Yumi Aoyama Akiko Ito Kayoko Suzuki Tamio Suzuki Atsushi Tanemura Masaaki Ito Ichiro Katayama Naoki Oiso Yuji Kagohashi Shinichi Sugiura Kazuyoshi Fukai Yoko Funasaka Toshiharu Yamashita Kayoko Matsunaga |
| |
Institution: | 1. Division of Dermatology, Department of Internal Related Graduate School of Medicine, Kobe University, Kobe, Japan;2. Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan;3. Department of Dermatology, Niigata University Medical and Dental Hospital, Niigata, Japan;4. Department of Dermatology, Kariya Toyota General Hospital, Kariya, Japan;5. Department of Dermatology, Yamagata University Faculty of Medicine, Yamagata, Japan;6. Department of Dermatology, Course of Integrated Medicine Graduate School of Medicine, Osaka University, Osaka, Japan;7. Department of Dermatology, Niigata University Graduate School of Medicine and Dental Science, Niigata, Japan;8. Department of Dermatology, Kinki University Faculty of Medicine, Osaka‐Sayama;9. Japanese Society for Dermatoallergology and Contact Dermatitis, Tokyo;10. Department of Healthcare Administration, Nagoya University Graduate School of Medicine, Nagoya, Japan;11. Department of Dermatology, Osaka City University Graduate School of Medicine, Osaka, Japan;12. Department of Dermatology, Nippon Medical School, Tokyo, Japan;13. Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan;14. Department of Dermatology, Fujita Health University School of Medicine, Toyoake, Japan |
| |
Abstract: | Because some users develop depigmentation after the use of melanogenesis‐inhibiting products containing the quasi‐drug ingredient Rhododenol, Japanese Dermatological Association (JDA) established a Special Committee on the Safety of Cosmetics Containing Rhododenol on July 17, 2013 and management guide for dermatologists has been updated on the website in order to delineate the diagnostic criteria for Rhododenol‐induced leukoderma and provides a broad guide for standard treatment based on current knowledge. This guide is produced on the basis of the guide (version 7) updated on June 20, 2014 in the website. Rhododenol‐induced leukoderma refers to depigmentation of varying severity that develops after the use of cosmetics containing Rhododenol, mainly at the site of use. In most cases, repigmentation of part or all the affected area is evident after discontinuation. Histopathologically cellular infiltration around the hair follicles and melanophages are present in most cases. The number of melanocytes in the lesion is declined but not totally absent in most cases. Rhododenol itself is a good substrate for tyrosinase, resulting in the formation of Rhododenol metabolites (e.g., Rhododenol quinone). Melanocytes are damaged by Rhododenol metabolites during the subsequent metabolic process. The continued use of cosmetics containing Rhododenol thus induces tyrosinase activity‐dependent cytotoxicity in melanocytes in the epidermis at application sites, resulting in decreasing the amount of melanin produced by melanocytes; the addition of some other factor to this process is believed to subsequently cause the decrease or disappearance of melanocytes themselves from the epidermis. |
| |
Keywords: | cosmetics leukoderma Rhododenol skin‐lightening agent ultraviolet light irradiation |
|
|